Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 3/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102314 | 1.00 | EHMT2 (0.49) | EHMT2SMOMMP1MMP3MMP9 | |
| SCHEMBL4187223 | 1.00 | EHMT2 (0.49) | EHMT2SMOMMP1MMP3MMP9 | |
| SCHEMBL30974749 | 0.92 | SMO (0.47) | EHMT2SMOMMP1MMP3MMP9 | |
| SCHEMBL5134174 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AGAAPOLB | |
| SCHEMBL5972097 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AGAAPOLB | |
| SCHEMBL5064255 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AGAAPOLB | |
| SCHEMBL5061447 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AGAAPOLB | |
| SCHEMBL5064737 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AGAAPOLB | |
| SCHEMBL23040245 | 0.83 | MMP1 (0.48) | EHMT2SMOMMP1MMP3MMP9 | |
| SCHEMBL29270893 | 0.83 | MMP1 (0.48) | EHMT2SMOMMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1122242-B1 | CYANOPHENYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-20050124625-A1 | Piperazine derivatives and their use as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-09 | — | — | US | disclosed |
| WO-2005040136-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20040010037-A1 | Cyanophenyl derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2004-01-15 | — | — | US | disclosed |
| US-6673799-B1 | INHIBITS BINDING TO ANDROGEN RECEPTOR; ANTIANDROGEN | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1122242-A1 | CYANOPHENYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124625-A1 | Piperazine derivatives and their use as modulators of nuclear hormone receptor function | NR5A2, NR4A2, GPER1 | EHMT2 701/4885SMO 1459/4885MMP1 4578/4885 |
| US-20040010037-A1 | Cyanophenyl derivative | BPHL, AR, KLK3 | EHMT2 578/4885SMO 287/4885MMP1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.